Sofgen Pharma

Sofgen Pharma Gross Margin

The Gross Margin of Sofgen Pharma (PROCF) as of Oct 19, 2026 is 51.23 %. In the previous year, Gross Margin was 56.16 % — a change of -8.79% (lower).

Gross Margin

51.23 %

YoY

-8.79%

Last updated:

Gross Margin of Sofgen Pharma is 2024 51.23 % . Gross Margin of Sofgen Pharma was 2023 56.16 % . It decreases by -8.79% lower compared to the previous year.

For Sofgen Pharma, the gross margin of 51.2% is down versus 57.7% a few years ago.

The Sofgen Pharma Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2019
56.19 USD
Jan 1, 2020
57.71 USD
Jan 1, 2021
56.99 USD
Jan 1, 2022
58.32 USD
Jan 1, 2023
56.16 USD
Jan 1, 2024
51.23 USD
The Sofgen Pharma Gross Margin history
YEARGross MarginYoY
51.23 %-8.79%
56.16 %-3.70%
58.32 %+2.33%
56.99 %-1.25%
57.71 %+2.70%
56.19 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sofgen Pharma Stock analysis

What does Sofgen Pharma do? Sofgen Pharma SA, listed under the ticker PROCF with ISIN LU2376511205, is a pharmaceutical company headquartered in Luxembourg. The company operates within the Health Care sector, specifically in the Pharmaceuticals industry. Sofgen Pharma employs approximately 5,500 people and completed its initial public offering on December 9, 2019. The company's website is https://www.procapsgroup.com/. Sofgen Pharma SA develops, manufactures, and sells prescription drugs and products featuring unique combinations and pharmaceutical forms, alongside nutritional supplements such as omega-3 fish oils and high-potency clinical compounds. The company organizes its operations through five business units: Diabetrics, Farma Procaps, Softi Gel, Vital Care, and Clinical Specialties. Diabetrics focuses on diabetes solutions. Farma Procaps is involved in formulating, manufacturing, and marketing branded prescription drugs in Latin America. Softi Gel offers contract drug development and manufacturing services to other pharmaceutical companies. Vital Care specializes in developing, manufacturing, and marketing consumer healthcare products. Clinical Specialties is dedicated to the development, manufacturing, and marketing of complex drugs. The company's business model emphasizes specialized pharmaceutical solutions and consumer health products, with a global operational footprint. Sofgen Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sofgen Pharma stock

Gross Margin of Sofgen Pharma is 51.23 % in 2024.

Gross Margin of Sofgen Pharma changed from 56.16 % to 51.23 %, representing a -8.79% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Sofgen Pharma since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Sofgen Pharma with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Sofgen Pharma

All Key Metrics — Sofgen Pharma